Alimera Sciences (ALIM) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ALIM Stock Forecast


Alimera Sciences stock forecast is as follows: an average price target of $5.75 (represents a 3.79% upside from ALIM’s last price of $5.54) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.

ALIM Price Target


The average price target for Alimera Sciences (ALIM) is $5.75 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $5.50. This represents a potential 3.79% upside from ALIM's last price of $5.54.

ALIM Analyst Ratings


Hold

According to 9 Wall Street analysts, Alimera Sciences's rating consensus is 'Hold'. The analyst rating breakdown for ALIM stock is 1 'Strong Buy' (11.11%), 2 'Buy' (22.22%), 5 'Hold' (55.56%), 1 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).

Alimera Sciences Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 25, 2024Yi ChenH.C. Wainwright$6.00$5.548.30%8.30%
Jun 24, 2024Chase KnickerbockerCraig-Hallum$5.50$5.54-0.72%-0.72%
Jul 28, 2022-H.C. Wainwright$9.00$5.4963.93%62.45%
May 10, 2022-H.C. Wainwright$8.00$5.0558.42%44.40%
Row per page
Go to

The latest Alimera Sciences stock forecast, released on Jun 25, 2024 by Yi Chen from H.C. Wainwright, set a price target of $6.00, which represents a 8.30% increase from the stock price at the time of the forecast ($5.54), and a 8.30% increase from ALIM last price ($5.54).

Alimera Sciences Price Target by Period


1M3M12M
# Anlaysts--2
Avg Price Target--$5.75
Last Closing Price$5.54$5.54$5.54
Upside/Downside-100.00%-100.00%3.79%

In the current month, the average price target of Alimera Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Alimera Sciences's last price of $5.54. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jun 25, 2024Alliance Global PartnersBuyNeutralDowngrade
Jun 25, 2024H.C. Wainwright-NeutralDowngrade
Jun 24, 2024Craig-Hallum-HoldDowngrade
Jun 12, 2023Raymond James-Strong BuyUpgrade
Jun 12, 2023Credit Suisse-NeutralDowngrade
Jun 12, 2023Morgan Stanley-UnderweightDowngrade
Jun 12, 2023BMO Capital-Market PerformDowngrade
Jun 12, 2023Scotiabank-OutperformUpgrade
Jun 12, 2023William Blair-OutperformUpgrade
Jun 12, 2023Alliance Global Partners-BuyUpgrade
Row per page
Go to

Alimera Sciences's last stock rating was published by Alliance Global Partners on Jun 25, 2024. The company Downgrade its ALIM rating from "Buy" to "Neutral".

Alimera Sciences Financial Forecast


Alimera Sciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$26.31M$23.36M$17.54M$13.55M$14.03M$13.60M$14.60M$11.90M$13.96M$12.15M$21.70M$11.21M$13.77M$12.47M$10.04M$14.54M$17.35M$12.85M
Avg Forecast$35.90M$31.80M$32.20M$27.90M$33.03M$29.97M$29.57M$25.93M$29.90M$27.43M$25.74M$22.25M$24.33M$22.70M$20.47M$12.30M$14.63M$15.05M$13.14M$12.53M$13.40M$12.37M$16.04M$11.40M$13.43M$10.89M$6.58M$14.09M$14.99M$12.79M
High Forecast$35.90M$31.80M$32.20M$27.90M$33.03M$29.97M$29.57M$25.93M$29.90M$27.43M$25.74M$22.25M$24.33M$22.70M$20.47M$12.30M$14.63M$15.05M$13.14M$12.53M$13.40M$12.37M$16.04M$11.40M$13.43M$10.89M$6.58M$14.09M$14.99M$12.79M
Low Forecast$35.90M$31.80M$32.20M$27.90M$33.03M$29.97M$29.57M$25.93M$29.90M$27.43M$25.74M$22.25M$24.33M$22.70M$20.47M$12.30M$14.63M$15.05M$13.14M$12.53M$13.40M$12.37M$16.04M$11.40M$13.43M$10.89M$6.58M$14.09M$14.99M$12.79M
# Analysts111111111211211111111111464474
Surprise %------------1.08%1.03%0.86%1.10%0.96%0.90%1.11%0.95%1.04%0.98%1.35%0.98%1.03%1.15%1.52%1.03%1.16%1.00%

Alimera Sciences's average Quarter revenue forecast for Mar 24 based on 1 analysts is $22.25M, with a low forecast of $22.25M, and a high forecast of $22.25M. ALIM's average Quarter revenue forecast represents a -15.44% decrease compared to the company's last Quarter revenue of $26.31M (Dec 23).

Alimera Sciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111111211211111111111464474
EBITDA------------$3.76M$-6.24M$-14.17M$-2.62M$-1.43M$-2.75M$-1.30M$-3.46M$-2.12M$-2.34M$10.19M$-1.67M$1.01M$1.35M$-505.00K$791.00K$2.15M$-1.16M
Avg Forecast$-292.06K$-258.70K$-261.96K$-226.98K$-268.74K$-243.79K$-240.53K$-210.98K$-243.24K$-223.16K$-209.41K$-4.80M$-197.96K$-184.67K$-166.50K$-3.79M$-1.52M$-122.41K$-106.87K$-3.00M$-109.05K$-100.64K$-130.49K$-1.39M$-109.29K$-88.61K$-53.56K$1.03M$-121.98K$-104.03K
High Forecast$-292.06K$-258.70K$-261.96K$-226.98K$-268.74K$-243.79K$-240.53K$-210.98K$-243.24K$-223.16K$-209.41K$-3.84M$-197.96K$-184.67K$-166.50K$-3.03M$-1.22M$-122.41K$-106.87K$-2.40M$-109.05K$-100.64K$-130.49K$-1.11M$-109.29K$-88.61K$-53.56K$1.23M$-121.98K$-104.03K
Low Forecast$-292.06K$-258.70K$-261.96K$-226.98K$-268.74K$-243.79K$-240.53K$-210.98K$-243.24K$-223.16K$-209.41K$-5.76M$-197.96K$-184.67K$-166.50K$-4.55M$-1.83M$-122.41K$-106.87K$-3.60M$-109.05K$-100.64K$-130.49K$-1.67M$-109.29K$-88.61K$-53.56K$821.17K$-121.98K$-104.03K
Surprise %-------------19.01%33.76%85.12%0.69%0.93%22.44%12.20%1.15%19.41%23.28%-78.05%1.20%-9.26%-15.25%9.43%0.77%-17.58%11.18%

1 analysts predict ALIM's average Quarter EBITDA for Mar 24 to be $-4.80M, with a high of $-3.84M and a low of $-5.76M. This is -227.42% lower than Alimera Sciences's previous annual EBITDA (Dec 23) of $3.76M.

Alimera Sciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111111211211111111111464474
Net Income------------$-3.78M$-1.35M$-10.03M$-8.30M$-3.78M$-5.26M$-3.12M$-7.76M$-4.11M$-4.18M$7.57M$-3.65M$-977.00K$-618.00K$-2.55M$-1.20M$498.00K$-3.14M
Avg Forecast$6.53M$3.26M$3.26M$-543.84K$5.98M$1.90M$1.63M$-1.36M$1.99M$-543.84K$-1.99M$-7.32M$1.09M$6.53M$271.92K$-5.79M$-2.96M$-21.75M$-36.44M$-4.57M$-22.84M$-28.55M$57.65M$-3.04M$-2.36M$-18.22M$-67.98M$-1.55M$-16.10M$-29.91M
High Forecast$6.53M$3.26M$3.26M$-543.84K$5.98M$1.90M$1.63M$-1.36M$1.99M$-543.84K$-1.99M$-5.86M$1.09M$6.53M$271.92K$-4.63M$-2.37M$-21.75M$-36.44M$-3.66M$-22.84M$-28.55M$58.97M$-2.43M$-2.36M$-18.22M$-67.98M$-1.24M$-16.10M$-29.91M
Low Forecast$6.53M$3.26M$3.26M$-543.84K$5.98M$1.90M$1.63M$-1.36M$1.99M$-543.84K$-1.99M$-8.78M$1.09M$6.53M$271.92K$-6.94M$-3.55M$-21.75M$-36.44M$-5.49M$-22.84M$-28.55M$56.32M$-3.65M$-2.36M$-18.22M$-67.98M$-1.87M$-16.10M$-29.91M
Surprise %-------------3.48%-0.21%-36.88%1.43%1.28%0.24%0.09%1.70%0.18%0.15%0.13%1.20%0.41%0.03%0.04%0.77%-0.03%0.10%

Alimera Sciences's average Quarter net income forecast for Sep 21 is $-28.55M, with a range of $-28.55M to $-28.55M. ALIM's average Quarter net income forecast represents a -477.41% decrease compared to the company's last Quarter net income of $7.57M (Jun 21).

Alimera Sciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111111211211111111111464474
SG&A------------$14.15M$11.55M$10.81M$9.97M$9.10M$9.86M$9.81M$10.09M$10.37M$8.56M$8.69M$8.23M$8.44M$7.38M$7.36M$8.85M$10.31M$9.56M
Avg Forecast$23.32M$20.65M$20.91M$18.12M$21.46M$19.46M$19.20M$16.84M$19.42M$17.82M$16.72M$12.41M$15.80M$14.74M$13.29M$9.81M$7.47M$9.77M$8.53M$7.75M$8.71M$8.03M$10.42M$6.86M$8.73M$7.07M$4.28M$11.49M$9.74M$8.31M
High Forecast$23.32M$20.65M$20.91M$18.12M$21.46M$19.46M$19.20M$16.84M$19.42M$17.82M$16.72M$14.89M$15.80M$14.74M$13.29M$11.77M$8.96M$9.77M$8.53M$9.30M$8.71M$8.03M$10.42M$8.23M$8.73M$7.07M$4.28M$13.79M$9.74M$8.31M
Low Forecast$23.32M$20.65M$20.91M$18.12M$21.46M$19.46M$19.20M$16.84M$19.42M$17.82M$16.72M$9.92M$15.80M$14.74M$13.29M$7.85M$5.97M$9.77M$8.53M$6.20M$8.71M$8.03M$10.42M$5.49M$8.73M$7.07M$4.28M$9.19M$9.74M$8.31M
Surprise %------------0.90%0.78%0.81%1.02%1.22%1.01%1.15%1.30%1.19%1.07%0.83%1.20%0.97%1.04%1.72%0.77%1.06%1.15%

Alimera Sciences's average Quarter SG&A projection for Mar 24 is $12.41M, based on 1 Wall Street analysts, with a range of $9.92M to $14.89M. The forecast indicates a -12.31% fall compared to ALIM last annual SG&A of $14.15M (Dec 23).

Alimera Sciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111111211211111111111464474
EPS------------$-0.07$-0.04$-1.24$-1.18$-0.54$-0.75$-0.45$-1.11$-0.59$-0.60$1.03$-0.63$-0.18$-0.12$-0.51$-0.24$0.08$-0.60
Avg Forecast$0.12$0.06$0.06$-0.01$0.11$0.04$0.03$-0.03$0.04$-0.01$-0.04$-0.06$0.02$0.12$0.01$-0.52$-0.34$-0.40$-0.67$-0.74$-0.42$-0.53$1.06$-0.54$-0.04$-0.34$-1.25$-0.40$-0.30$-0.55
High Forecast$0.12$0.06$0.06$-0.01$0.11$0.04$0.03$-0.03$0.04$-0.01$-0.04$-0.06$0.02$0.12$0.01$-0.52$-0.34$-0.40$-0.67$-0.74$-0.42$-0.53$1.08$-0.54$-0.04$-0.34$-1.25$-0.40$-0.30$-0.55
Low Forecast$0.12$0.06$0.06$-0.01$0.11$0.04$0.03$-0.03$0.04$-0.01$-0.04$-0.06$0.02$0.12$0.01$-0.52$-0.34$-0.40$-0.67$-0.74$-0.42$-0.53$1.04$-0.54$-0.04$-0.34$-1.25$-0.40$-0.30$-0.55
Surprise %-------------3.48%-0.35%-248.00%2.29%1.61%1.88%0.67%1.49%1.40%1.14%0.97%1.17%4.15%0.36%0.41%0.61%-0.27%1.09%

According to 1 Wall Street analysts, Alimera Sciences's projected average Quarter EPS for Sep 21 is $-0.53, with a low estimate of $-0.53 and a high estimate of $-0.53. This represents a -150.97% decrease compared to ALIM previous annual EPS of $1.03 (Jun 21).

Alimera Sciences Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CYTHCyclo Therapeutics$0.70$0.9535.71%Buy
ORGOOrganogenesis$4.02$5.0024.38%Buy
ALIMAlimera Sciences$5.54$5.753.79%Hold
LFCRLifecore Biomedical$6.98$6.50-6.88%Buy

ALIM Forecast FAQ


Is Alimera Sciences a good buy?

No, according to 9 Wall Street analysts, Alimera Sciences (ALIM) is considered a 'Hold'. The rating consensus is based on 1 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of ALIM's total ratings.

What is ALIM's price target?

Alimera Sciences (ALIM) average price target is $5.75 with a range of $5.5 to $6, implying a 3.79% from its last price of $5.54. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Alimera Sciences stock go up soon?

According to Wall Street analysts' prediction for ALIM stock, the company can go up by 3.79% (from the last price of $5.54 to the average price target of $5.75), up by 8.30% based on the highest stock price target, and down by -0.72% based on the lowest stock price target.

Can Alimera Sciences stock reach $8?

ALIM's average twelve months analyst stock price target of $5.75 does not support the claim that Alimera Sciences can reach $8 in the near future.

What are Alimera Sciences's analysts' financial forecasts?

Alimera Sciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $118.5M (high $118.5M, low $118.5M), average EBITDA is $-964K (high $-964K, low $-964K), average net income is $8.16M (high $8.16M, low $8.16M), average SG&A $76.97M (high $76.97M, low $76.97M), and average EPS is $0.15 (high $0.15, low $0.15). ALIM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $127.8M (high $127.8M, low $127.8M), average EBITDA is $-1.04M (high $-1.04M, low $-1.04M), average net income is $12.51M (high $12.51M, low $12.51M), average SG&A $83.01M (high $83.01M, low $83.01M), and average EPS is $0.23 (high $0.23, low $0.23).

Did the ALIM's actual financial results beat the analysts' financial forecasts?

Based on Alimera Sciences's last annual report (Dec 2023), the company's revenue was $80.75M, beating the average analysts forecast of $79.8M by 1.20%. Apple's EBITDA was $6.82M, missing the average prediction of $-4.341M by -257.01%. The company's net income was $-20.132M, missing the average estimation of $2.1M by -1058.96%. Apple's SG&A was $46.48M, missing the average forecast of $53.65M by -13.37%. Lastly, the company's EPS was $-0.79, beating the average prediction of $-0.37 by 113.51%. In terms of the last quarterly report (Dec 2023), Alimera Sciences's revenue was $26.31M, beating the average analysts' forecast of $24.33M by 8.11%. The company's EBITDA was $3.76M, missing the average prediction of $-198K by -2001.39%. Alimera Sciences's net income was $-3.781M, missing the average estimation of $1.09M by -447.62%. The company's SG&A was $14.15M, missing the average forecast of $15.8M by -10.49%. Lastly, the company's EPS was $-0.0695, missing the average prediction of $0.02 by -447.50%